<ѻýҕl>Targeted Combo Fails in EGFR-Mutant NSCLCѻýҕl> Osimertinib-bevacizumab no better than osimertinib alone Jan 07, 2021
<ѻýҕl>Baby Boys Get Cancer From Mom During Birthѻýҕl> Report highlights potential fetal implications of undiagnosed maternal cervical cancer Jan 06, 2021
<ѻýҕl>Lorlatinib Shows 'Striking' CNS Activity in ALK Lung Cancerѻýҕl> But unusual adverse events may hold therapy back Nov 18, 2020
<ѻýҕl>CDK4/6 Inhibitor in SCLC Cuts Chemo-Induced Myelosuppressionѻýҕl> Reduced severe neutropenia and less need for supportive care with trilaciclib Oct 20, 2020
<ѻýҕl>Dual Checkpoint Blockade With Some Chemo Boosts OS in NSCLCѻýҕl> Nivolumab-ipilimumab with two cycles of chemotherapy improved survival, regardless of histology or PD-L1 status Oct 17, 2020
<ѻýҕl>Drug Active in 'Undruggable' KRAS-Mutant NSCLCѻýҕl> Responses in a third of patients, disease control rate approaching 90% Sep 20, 2020
<ѻýҕl>A Closer Look at FDA Decision to Pull Lorcaserinѻýҕl> More cancers, multiple primaries, and deaths in CAMELLIA-TIMI 61 influenced agency decision Sep 09, 2020
<ѻýҕl>Even 'Light' Smoking Ups Lung Cancer Riskѻýҕl> Mortality approaches that of heavy smokers Sep 09, 2020
<ѻýҕl>In Lupus, Older Age and Male Sex Raise Cancer Riskѻýҕl> Role of most medications, though, not yet clear Aug 21, 2020
<ѻýҕl>Chemo-Free Regimen Boosts OS in Mesotheliomaѻýҕl> Big advantage for nivolumab-ipilimumab in nonepithelioid tumors drives advantage over chemo Aug 09, 2020
<ѻýҕl>Another ALK Drug Tops Crizotinib in First-Line NSCLCѻýҕl> Ensartinib doubled PFS over older standard, with improved CNS activity Aug 08, 2020
<ѻýҕl>COVID-19 More Deadly Than Cancer Itself?ѻýҕl> Highlights from the AACR conference on COVID-19 and cancer Jul 24, 2020
<ѻýҕl>The Serious Conversation: Delivering Bad News by Telemedicineѻýҕl> As office visits move online, clinicians discuss breaking life-changing diagnoses virtually Jul 13, 2020
<ѻýҕl>Cancer Immunotherapy Tied to Severe COVID-19 Outcomesѻýҕl> Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
<ѻýҕl>COVID-19 in Thoracic Cancer Patients a Killerѻýҕl> Most cancer patients hospitalized May 28, 2020
<ѻýҕl>Paradigm Shift Coming for Early NSCLC?ѻýҕl> Postoperative osimertinib doubles DFS in patients with stages Ib-IIIa EGFR+ lung cancer May 28, 2020
<ѻýҕl>End of Life and COVID-19; DCIS Doubles Cancer Risk; Training for 'Bad News'ѻýҕl> News, features, and commentary about cancer-related issues May 28, 2020
<ѻýҕl>6-Week Keytruda Safe, Effective in Melanomaѻýҕl> Schedule gets FDA approval for all adult indications Apr 30, 2020
<ѻýҕl>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancersѻýҕl> Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<ѻýҕl>How Prevalent Is Checkpoint Inhibitor Thyroid Dysfunction, Really?ѻýҕl> Real-world data offer word of caution for oncologists Apr 01, 2020
<ѻýҕl>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleedsѻýҕl> Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<ѻýҕl>No DNA Damage Seen With Single Low-Dose CT Scanѻýҕl> Some reassurance for annual lung cancer screening safety Mar 10, 2020
<ѻýҕl>Rush Limbaugh's Advanced Lung Cancerѻýҕl> Conservative talk show host announces diagnosis Feb 13, 2020
<ѻýҕl>PD-1 vs PD-L1 Inhibitors: Do Outcomes Differ?ѻýҕl> Meta-analysis suggests they aren't equivalent Dec 27, 2019
<ѻýҕl>Pembrolizumab Shows Survival Benefit in KRAS-Mutant NSCLCѻýҕl> Improved OS, PFS, and response rates compared to chemo in first-line Dec 16, 2019
<ѻýҕl>AHA Dedicates $20 Million to Youth Vaping Researchѻýҕl> Association and partners aim to "hold e-cigarette companies publicly accountable for their lies" Nov 16, 2019
<ѻýҕl>Rheumatoid Arthritis Is No Bar to Cancer Immunotherapyѻýҕl> Small study finds flares common with checkpoint inhibitors, but few patients stopped treatment because of them Nov 13, 2019
<ѻýҕl>Abnormal Shadow on Chest Radiographѻýҕl> Culture findings were key in making the diagnosis Nov 11, 2019
<ѻýҕl>Notable OS Gains with Dual Immunotherapy in Advanced NSCLCѻýҕl> Secondary analysis of CheckMate 227 brings more good news for nivolumab-ipilimumab combo Sep 28, 2019
<ѻýҕl>BCG Vax: A Shot Against Lung Cancer in Native Populations?ѻýҕl> 60-year follow-up data from a vaccine trial found surprising results Sep 25, 2019
<ѻýҕl>Post-Immunotherapy SBRT Boosts Outcomes in Advanced NSCLCѻýҕl> Increased systemic response rate, disease control rate, and PFS in phase II trial Sep 17, 2019
<ѻýҕl>Anti-PD-1/L1 for NSCLC Sparks Talk of the 'C' Wordѻýҕl> Unprecedented survival at 3 and 5 years, but investigators reluctant to say "cure" Sep 10, 2019
<ѻýҕl>'Dirtier' Drugs Step Aside in RET-Positive NSCLCѻýҕl> Over two-thirds of patients respond to selective RET inhibitor Sep 09, 2019
<ѻýҕl>TMB in Lung Cancer: 'Not Ready for Prime Time'ѻýҕl> No association between tumor mutational burden and outcomes in three trials Sep 09, 2019
<ѻýҕl>Peter Fonda’s Lung Cancer Battleѻýҕl> Farewell, Easy Rider: legendary actor dead at 79 Aug 29, 2019
<ѻýҕl>Small Cancer Risk With Lung Micronodulesѻýҕl> Supports classifying small nodules as negative scan result Jul 10, 2019
<ѻýҕl>More Clarity to Steroids' Effect on Anti-PD-1 Therapyѻýҕl> Adverse effects driven by palliative indications associated with poor prognosis Jun 27, 2019
<ѻýҕl>Rheumatologist's Primer on Checkpoint Inhibitorsѻýҕl> Specialist reviews the landscape of cancer drugs' autoimmune side effects Apr 09, 2019
<ѻýҕl>Durable Responses With Keytruda in Later-Line SCLCѻýҕl> Plus umbralisib in marginal zone lymphoma and a next-generation TRK-targeted agent Apr 04, 2019
<ѻýҕl>MET Inhibitor Rescues Some Targeted Tx Failures in NSCLCѻýҕl> Savolitinib promising in patients with MET-based resistance to EGFR inhibition Apr 01, 2019 video